Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/2/2024 | $29.00 | Outperform | Leerink Partners |
12/5/2023 | $38.00 | Overweight | KeyBanc Capital Markets |
5/5/2023 | $60.00 | Overweight | Piper Sandler |
12/19/2022 | $23.00 | Neutral | Goldman |
3/1/2022 | $55.00 | Buy | Citigroup |
11/19/2021 | $82.00 → $49.00 | Overweight → Equal-Weight | Morgan Stanley |
11/19/2021 | $87.00 | Overweight | Piper Sandler |
11/11/2021 | $80.00 → $52.00 | Buy → Neutral | B of A Securities |
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
8-K - Schrodinger, Inc. (0001490978) (Filer)
S-8 - Schrodinger, Inc. (0001490978) (Filer)
10-Q - Schrodinger, Inc. (0001490978) (Filer)
Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00
KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00
Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00
Second Quarter Total Revenue of $47.3 Million, Software Revenue of $35.4 Million Launches Major Initiative to Expand Application of Computational Tools for Predictive Toxicology Initial Clinical Data Expected for SGR-1505 in 1H25, SGR-2921 and SGR-3515 Data in 2H25 Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the second quarter of 2024. "We are very pleased with our results for the second quarter. We delivered 21% software revenue growth, and we see many opportunities for customers to increase their scale of adoption of our technology. Our recently
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecule
First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for Initial Phase 1 Data Readouts in Late 2024 or 2025 Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the first quarter of 2024. "Over the past year, we have witnessed unprecedented interest in computational drug discovery, and we are excited by the growing appreciation for using computation to drive pharmaceutical innovation. We are exci
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on September 13, 2024, the company granted restricted stock units (RSUs) with respect to 7,025 shares of the company's common stock to eight newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on August 14, 2024, the company granted restricted stock units (RSUs) with respect to 7,500 shares of the company's common stock to 13 newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a com
Schrödinger (NASDAQ:SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The live presentation will take place on Wednesday, September 4, 2024, at 3:20 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discover
During the last three months, 4 analysts shared their evaluations of Schrodinger (NASDAQ:SDGR), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $30.25, a high estimate of $37.00, and a low estimate of $25.00. This current average has decreased by 12.75% from t
Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $30 to $25.
Leerink Partners analyst Mani Foroohar initiates coverage on Schrodinger (NASDAQ:SDGR) with a Outperform rating and announces Price Target of $29.
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005040/en/Arun Oberoi was appointed to Schrödinger's Board of Directors in May 2022. He will serve on the company's Audit Committee. (Photo: Business Wire) "We are very pleased to welcome Arun to our Board," said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger. "Aru
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)